4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

4D Molecular Therapeutics (NASDAQ:FDMT) had its target price hoisted by investment analysts at Royal Bank Of Canada from $32.00 to $35.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada’s price objective indicates a potential upside of 306.50% from the company’s current price.

Several other research analysts also recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, January 21st. Chardan Capital restated a “buy” rating and set a $26.00 price objective on shares of 4D Molecular Therapeutics in a research report on Thursday. Barclays initiated coverage on 4D Molecular Therapeutics in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $33.00 price objective on the stock. Finally, Wall Street Zen lowered 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $32.71.

4D Molecular Therapeutics Stock Performance

FDMT stock opened at $8.61 on Thursday. The company has a market capitalization of $439.54 million, a P/E ratio of -3.56 and a beta of 2.99. The company has a fifty day moving average price of $8.75 and a 200-day moving average price of $9.10. 4D Molecular Therapeutics has a 52-week low of $2.23 and a 52-week high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Wednesday, March 18th. The company reported $0.43 earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.96. 4D Molecular Therapeutics had a negative net margin of 164.43% and a negative return on equity of 31.75%. The company had revenue of $85.09 million for the quarter, compared to analysts’ expectations of $30.86 million. As a group, sell-side analysts forecast that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Martingale Asset Management L P boosted its position in shares of 4D Molecular Therapeutics by 12.4% during the 4th quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock valued at $88,000 after purchasing an additional 1,303 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in 4D Molecular Therapeutics by 3.7% in the third quarter. Dimensional Fund Advisors LP now owns 58,006 shares of the company’s stock valued at $504,000 after buying an additional 2,069 shares during the period. Russell Investments Group Ltd. lifted its stake in 4D Molecular Therapeutics by 11.7% in the second quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company’s stock valued at $81,000 after buying an additional 2,284 shares during the period. Prelude Capital Management LLC boosted its holdings in shares of 4D Molecular Therapeutics by 11.1% during the 3rd quarter. Prelude Capital Management LLC now owns 23,000 shares of the company’s stock worth $200,000 after buying an additional 2,300 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its holdings in shares of 4D Molecular Therapeutics by 117.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock worth $43,000 after buying an additional 2,674 shares in the last quarter. 99.27% of the stock is owned by institutional investors.

4D Molecular Therapeutics News Roundup

Here are the key news stories impacting 4D Molecular Therapeutics this week:

• Positive Sentiment: High-profile firms reiterated bullish views and raised targets, supporting upside potential — HC Wainwright reaffirmed a “buy” and set a $36 target (very large implied upside). Read More.
• Positive Sentiment: Royal Bank of Canada raised its price target to $35 and gave an “outperform” rating, signaling strong analyst conviction on mid/long-term value. Read More.
• Positive Sentiment: Chardan Capital reaffirmed a “buy” with a $26 target, adding another supportive research note. Read More.
• Positive Sentiment: Fundamental beat: 4D reported Q4 EPS of $0.43 (well ahead of consensus) and revenue of $85.1M, which typically supports higher valuations and reduces near-term execution risk. Read More.
• Neutral Sentiment: Analyst commentary is mixed across the sector; some aggregation pieces note divergent views on FDMT which can increase intraday volatility without clear directional pressure. Read More.
• Neutral Sentiment: Short-interest reports in the latest feeds show anomalous/zero values (reports indicate increases but list 0 shares/NaN), suggesting the data feed is unreliable — this appears to be noise rather than a clear short-squeeze or large shorting event.
• Negative Sentiment: Cantor Fitzgerald issued a “hold” on FDMT, which can dampen momentum from the bullish notes and makes the street’s view less one-sided. Read More.
• Negative Sentiment: New risk disclosure: a TipRanks piece highlights reimbursement and pricing pressures that could materially affect the commercial outlook for FDMT’s gene therapies — a real demand/price-risk that can weigh on valuation and near-term sentiment. Read More.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.